

Contents

1. Introduction	1
2. Open session	2
3. Update on current activities on selection and rational use	3
3.1 Dissemination of the previous report of the Expert Committee (including the 13th Model List)	3
3.2 WHO Model Formulary and WHO Essential Medicines Library	4
3.3 Plans for further revisions of the Model List and <i>WHO model formulary</i>	4
3.4 Review of essential medicines for reproductive health	5
3.5 Review of the Interagency Emergency Health Kit 2005	5
3.6 Report of the WHO Advisory Committee on Safety of Medicinal Products	6
3.7 Update on current activities in the field of rational use of medicines	6
3.8 Report of the Critically Important Antibiotics for Human Health Meeting, Canberra, Australia, 15–17 February 2005	7
3.9 Update on the Priority Medicines Project	8
3.10 Collaboration with the International Society of Drug Bulletins	8
3.11 Discussion	8
4. Changes made in revising the Model List	9
4.1 Applications for deletions	9
4.1.1 Aminophylline and theophylline	9
4.1.2 Atropine	10
4.1.3 Calcium gluconate	10
4.1.4 Clonazepam	11
4.1.5 Codeine	11
4.1.6 Colchicine	12
4.1.7 Cromoglycic acid	12
4.1.8 Diethyltoluamide	13
4.1.9 Ergotamine	13
4.1.10 Ergometrine	14
4.1.11 Ether	14
4.1.12 Factors VIII and IX concentrates	15
4.1.13 Imipenem + cilastatin	16
4.1.14 Isoprenaline	17
4.1.15 Levofloxacin	17
4.1.16 Local anaesthetic, astringent or anti-inflammatory as antihaemorrhoidal medicines	18
4.1.17 Medroxyprogesterone acetate (depot injection 150mg/ml)	18
4.1.18 Medroxyprogesterone acetate (tablet 5mg)	19
4.1.19 Nalidixic acid	19
4.1.20 Niclosamide	20
4.1.21 Nifedipine	20
4.1.22 Oxamniquine	21

4.1.23	Polygeline	21
4.1.24	Procainamide	22
4.1.25	Pyrantel	22
4.1.26	Quinidine	23
4.1.27	Salbutamol	23
4.1.28	Silver nitrate eye solution	23
4.1.29	Sodium fluoride	24
4.1.30	Spectinomycin	24
4.1.31	Sun protection agents	25
4.1.32	Thioacetazone + isoniazid	25
4.1.33	Triclabendazole	27
4.2	Applications for additions	27
4.2.1	Caffeine citrate	27
4.2.2	Cefixime	28
4.2.3	Clotrimazole	28
4.2.4	Combination injectable contraceptives	29
4.2.5	Emtricitabine	29
4.2.6	Emtricitabine + tenofovir fixed-dose combination	30
4.2.7	Etonogestrel-releasing implant	30
4.2.8	Ibuprofen paediatric suspension	31
4.2.9	Levonorgestrel-releasing implant	32
4.2.10	Levonorgestrel-releasing IUD	32
4.2.11	Methadone and buprenorphine	33
4.2.12	Methoxyflurane	34
4.2.13	Miltefosine	35
4.2.14	Nifedipine	35
4.2.15	Mifepristone with misoprostol	36
4.2.16	Misoprostol, low dose	37
4.2.17	Nifedipine	38
4.2.18	Tenofovir	38
4.2.19	Zinc sulfate	39
4.3	Other changes	40
4.3.1	Alcuronium and vecuronium	40
4.3.2	Antiretroviral medicines	40
4.3.3	Ceftriaxone 1 g injection	41
4.3.4	Immunoglobulin, human normal	41
4.3.5	Labetalol	42
4.3.6	Prostaglandins for postpartum haemorrhage	43
5.	Reviews of sections of the Model List	43
5.1	Beta-lactam medicines	43
5.2	General anaesthetics and oxygen	44
5.3	Muscle relaxants	44
5.4	Ophthalmological preparations	44
6.	Rare diseases	44
7.	Future priorities	45
7.1	Summary of recommendations — additions, changes and deletions to the Model List	45
7.2	Methodological issues	48
7.3	Rational medicine use	48

Section	References	49
	Annex 1	
	The 14th WHO Model List of Essential Medicines	54
	Annex 2	
	The Anatomical Therapeutic Chemical (ATC) classification system	93
	Alphabetical list of essential medicines (with ATC classification code numbers)	112